8 completed, 1 unknown. 9 Phase 2, 4 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 8, Unknown 1 |
| Phase 3 | 4 | Completed 3, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow Extensively Drug-Resistant Tuberculosis: new trials by email Literature Review of Extensively Drug-Resistant Tuberculosis trials Research Report on Extensively Drug-Resistant Tuberculosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Pretomanid, Bedaquiline, moxifloxacin - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant | Phase 2 | Completed | Global Alliance for TB Drug Development | 26 | 2021-09-16 | 2025-01-17 |
| Economic Evaluation of New MDR TB Regimens Bedaquiline, Pretomanid, Moxifloxacin - Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis | Phase 2 / Phase 3 | Completed | Medecins Sans Frontieres, Netherlands | 73 | 2020-10-20 | 2024-04-22 |
| PRACTECAL-PKPD Sub Study Bedaquiline, Pretomanid, Moxifloxacin - Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis | Phase 2 / Phase 3 | Unknown | Medecins Sans Frontieres, Netherlands | 240 | 2019-08-06 | 2021-05-14 |
| Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) Bedaquiline, Pretomanid, Moxifloxacin - Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis | Phase 2 / Phase 3 | Completed | Medecins Sans Frontieres, Netherlands | 552 | 2017-01-01 | 2024-05-01 |
| An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis Linezolid, Bedaquiline, Levofloxacin - Tuberculosis, Multidrug Resistant Tuberculosis | Phase 2 / Phase 3 | Completed | University of Cape Town | 154 | 2015-11-12 | 2021-09-29 |
| Safety and Efficacy of Oral Immunomodulator in Tuberculosis (TB) and TB/HIV Patients V-5 immunitor - Tuberculosis | Phase 2 | Completed | Lisichansk Regional Tuberculosis Dispensary | 123 | 2010-01-01 | 2012-08-03 |
| TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB Linezolid, Placebo - Multi-drug Resistant Tuberculosis, Extensively Drug Resistant Tuberculosis | Phase 1 / Phase 2 | Completed | Centers for Disease Control and Prevention | 36 | 2009-04-01 | 2026-07-06 |
| Linezolid to Treat Extensively-Drug Resistant Tuberculosis Immediate Start Linezolid, Delayed Start Linezolid - Pulmonary Tuberculosis, Multidrug Resistant Tuberculosis | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 41 | 2008-07-01 | 2016-03-14 |
| A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB) Delamanid, Optimized Background Regimen (OBR), Placebo - Tuberculosis, Pulmonary, Tuberculosis, Multidrug Resistant | Phase 2 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 481 | 2008-05-08 | 2021-12-01 |
Tuberculosis, Multidrug-Resistant (9) · Tuberculosis, Pulmonary (6) · Tuberculosis (5) · Anemia (1) · Mycobacterium Infections (1) · Optic Nerve Diseases (1) · Peripheral Nervous System Diseases (1) · Thrombocytopenia (1)
Actinomycetales Infections (9) · Bacterial Infections (9) · Bacterial Infections and Mycoses (9) · Gram-Positive Bacterial Infections (9) · Infections (9) · Mycobacterium Infections (8) · Lung Diseases (6) · Respiratory Tract Diseases (6) · Respiratory Tract Infections (6) · Tuberculosis (4) · Blood Platelet Disorders (1) · Cranial Nerve Diseases (1) · Cytopenia (1) · Eye Diseases (1) · Hematologic Diseases (1)
Linezolid (6) · Moxifloxacin (5) · bedaquiline (5) · pretomanid (4) · Clofazimine (3) · Pyrazinamide (2) · Ethionamide (1) · Isoniazid (1) · Kanamycin (1) · Levofloxacin (1) · OPC-67683 (1) · V-5 immunitor (1) · stearic acid (1) · terizidone (1)
Medecins Sans Frontieres, Netherlands (3) · Centers for Disease Control and Prevention (1) · Global Alliance for TB Drug Development (1) · Lisichansk Regional Tuberculosis Dispensary (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · University of Cape Town (1)
South Africa (6) · Belarus (3) · South Korea (2) · Uzbekistan (2) · China (1) · Egypt (1) · Estonia (1) · Georgia (1) · Japan (1) · Latvia (1) · Peru (1) · Philippines (1) · Ukraine (1) · United States (1)
Antonio Lombardi, MD (1) · Bern Nyang'wa, MB BS, MPH (1) · Bern-Thomas Nyang'wa, MD (1) · Clifton Barry, Ph.D. (1) · Dmytro Butov, MD (1) · Jussi Saukkonen, MD (1) · Keertan Dheda, MBChB (1) · Nesri Padayachin, MBChB (1) · Sedona Sweeny (1) · Waffa El-Sadr, MD (1)
PMID 21182457, PMID 22670901, PMID 23075177, PMID 23131255, PMID 27868466, PMID 31932382, PMID 34489274, PMID 35175905, PMID 35698158, PMID 36546625, PMID 37980911, PMID 38842323, PMID 41917253, PMID 42270675